Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!
Carl Zeiss Meditec Yönetim
Yönetim kriter kontrolleri 4/4
Şu anda CEO hakkında yeterli bilgiye sahip değiliz.
Anahtar bilgiler
Markus Weber
İcra Kurulu Başkanı
€1.1m
Toplam tazminat
| CEO maaş yüzdesi | 40.5% |
| CEO görev süresi | 2.8yrs |
| CEO sahipliği | n/a |
| Yönetim ortalama görev süresi | 4.5yrs |
| Yönetim Kurulu ortalama görev süresi | 3.4yrs |
Son yönetim güncellemeleri
Here's Why We Think Carl Zeiss Meditec AG's (ETR:AFX) CEO Compensation Looks Fair for the time being
May 21
How Should Investors Feel About Carl Zeiss Meditec's (ETR:AFX) CEO Remuneration?
Feb 16
Recent updates
Some Investors May Be Worried About Carl Zeiss Meditec's (ETR:AFX) Returns On Capital
Sep 19Does Carl Zeiss Meditec (ETR:AFX) Have A Healthy Balance Sheet?
Sep 06Are Investors Undervaluing Carl Zeiss Meditec AG (ETR:AFX) By 27%?
Aug 23At €62.50, Is It Time To Put Carl Zeiss Meditec AG (ETR:AFX) On Your Watch List?
Aug 09Carl Zeiss Meditec AG's (ETR:AFX) 25% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/ERatio
Jul 11Returns On Capital At Carl Zeiss Meditec (ETR:AFX) Have Stalled
Jun 10Carl Zeiss Meditec AG's (ETR:AFX) Popularity With Investors Is Under Threat From Overpricing
May 26Carl Zeiss Meditec AG Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
May 11Calculating The Fair Value Of Carl Zeiss Meditec AG (ETR:AFX)
May 09Is There Now An Opportunity In Carl Zeiss Meditec AG (ETR:AFX)?
Mar 24Does Carl Zeiss Meditec (ETR:AFX) Have A Healthy Balance Sheet?
Mar 11Slowing Rates Of Return At Carl Zeiss Meditec (ETR:AFX) Leave Little Room For Excitement
Feb 12Calculating The Fair Value Of Carl Zeiss Meditec AG (ETR:AFX)
Jan 29What Does Carl Zeiss Meditec AG's (ETR:AFX) Share Price Indicate?
Dec 08Carl Zeiss Meditec (ETR:AFX) Is Experiencing Growth In Returns On Capital
Nov 08Carl Zeiss Meditec AG's (ETR:AFX) Intrinsic Value Is Potentially 37% Above Its Share Price
Oct 24Is Carl Zeiss Meditec (ETR:AFX) A Risky Investment?
Sep 24Should You Investigate Carl Zeiss Meditec AG (ETR:AFX) At €85.72?
Sep 08Calculating The Fair Value Of Carl Zeiss Meditec AG (ETR:AFX)
Jul 24We Like These Underlying Return On Capital Trends At Carl Zeiss Meditec (ETR:AFX)
Jun 19Should You Think About Buying Carl Zeiss Meditec AG (ETR:AFX) Now?
Jun 06Is Now The Time To Put Carl Zeiss Meditec (ETR:AFX) On Your Watchlist?
May 22Carl Zeiss Meditec AG's (ETR:AFX) Intrinsic Value Is Potentially 24% Below Its Share Price
Apr 19Carl Zeiss Meditec (ETR:AFX) Has A Pretty Healthy Balance Sheet
Feb 26Carl Zeiss Meditec's (ETR:AFX) Shareholders Will Receive A Bigger Dividend Than Last Year
Feb 10Here's Why We Think Carl Zeiss Meditec (ETR:AFX) Is Well Worth Watching
Jan 28Carl Zeiss Meditec (ETR:AFX) Has Announced That It Will Be Increasing Its Dividend To €1.10
Jan 12Carl Zeiss Meditec (ETR:AFX) Will Pay A Larger Dividend Than Last Year At €1.10
Dec 29Carl Zeiss Meditec (ETR:AFX) Has Announced That It Will Be Increasing Its Dividend To €1.10
Dec 14What Is Carl Zeiss Meditec AG's (ETR:AFX) Share Price Doing?
Nov 04Calculating The Intrinsic Value Of Carl Zeiss Meditec AG (ETR:AFX)
Oct 18Investors Will Want Carl Zeiss Meditec's (ETR:AFX) Growth In ROCE To Persist
Sep 12Carl Zeiss Meditec (ETR:AFX) Seems To Use Debt Rather Sparingly
Aug 25Returns On Capital At Carl Zeiss Meditec (ETR:AFX) Have Hit The Brakes
May 30Does Carl Zeiss Meditec (ETR:AFX) Have A Healthy Balance Sheet?
Feb 27Carl Zeiss Meditec's (ETR:AFX) Returns Have Hit A Wall
Feb 08Here's Why We Think Carl Zeiss Meditec (ETR:AFX) Is Well Worth Watching
Dec 12Carl Zeiss Meditec (ETR:AFX) Has Some Way To Go To Become A Multi-Bagger
Nov 06If You Like EPS Growth Then Check Out Carl Zeiss Meditec (ETR:AFX) Before It's Too Late
Sep 06Investors Met With Slowing Returns on Capital At Carl Zeiss Meditec (ETR:AFX)
Aug 08Here's Why We Think Carl Zeiss Meditec AG's (ETR:AFX) CEO Compensation Looks Fair for the time being
May 21Why Carl Zeiss Meditec's (ETR:AFX) Shaky Earnings Are Just The Beginning Of Its Problems
May 18Capital Allocation Trends At Carl Zeiss Meditec (ETR:AFX) Aren't Ideal
Apr 28Carl Zeiss Meditec AG's (ETR:AFX) Intrinsic Value Is Potentially 19% Below Its Share Price
Mar 09How Should Investors Feel About Carl Zeiss Meditec's (ETR:AFX) CEO Remuneration?
Feb 16CEO Tazminat Analizi
| Tarih | Toplam Tazminat | Maaş | Şirket Kazançları |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | €203m |
| Mar 31 2024 | n/a | n/a | €261m |
| Dec 31 2023 | n/a | n/a | €277m |
| Sep 30 2023 | €1m | €426k | €290m |
| Jun 30 2023 | n/a | n/a | €308m |
| Mar 31 2023 | n/a | n/a | €278m |
| Dec 31 2022 | n/a | n/a | €307m |
| Sep 30 2022 | €1m | €298k | €294m |
Tazminat ve Piyasa: Markus 'nin toplam tazminatı ($USD 1.16M ), German pazarındaki benzer büyüklükteki şirketler için ortalamanın altındadır ($USD 3.18M ).
Tazminat ve Kazançlar: Markus 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.
CEO
Markus Weber
2.8yrs
Görev süresi
€1,050,400
Tazminat
Dr. Markus Weber is CEO & Chairman of Management Board of Carl Zeiss Meditec AG from January 01, 2022 and served as its President since January 01, 2022 until December 2022. He joined ZEISS Semiconductor M...
Liderlik Ekibi
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| CEO & Chairman of Management Board | 2.8yrs | €1.05m | Veri yok | |
| CFO & Member of the Management Board | 6yrs | €799.30k | Veri yok | |
| Head of Global Regulatory & Clinical Affairs | 1.8yrs | Veri yok | Veri yok | |
| Chief Operating Officer | no data | Veri yok | Veri yok | |
| Director of Investor Relations | no data | Veri yok | Veri yok | |
| Chief Human Resources Officer | no data | Veri yok | Veri yok | |
| Chief Medical Officer for Global Ophthalmic Devices | 8yrs | Veri yok | Veri yok | |
| Head of Sales for Ophthalmic Devices & President of Carl Zeiss Meditec | 4.6yrs | Veri yok | Veri yok | |
| President of Ophthalmic Devices and Head of the Ophthalmic Devices Strategic & Digital Business Unit | 4.4yrs | Veri yok | Veri yok | |
| Head of the Microsurgery Strategic Business Unit - ZEISS Medical Technology | no data | Veri yok | Veri yok |
4.5yrs
Ortalama Görev Süresi
59yo
Ortalama Yaş
Deneyimli Yönetim: AFX 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 4.5 yıldır).
Yönetim Kurulu Üyeleri
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| Head of Global Regulatory & Clinical Affairs | 1.6yrs | Veri yok | Veri yok | |
| Chairman of the Supervisory Board | 4.3yrs | Veri yok | Veri yok | |
| Honorary Chairman of the Supervisory Board | 3.4yrs | €43.10k | Veri yok | |
| Member of the Supervisory Board | 4.3yrs | €36.00k | Veri yok | |
| Member of the Supervisory Board | 3.4yrs | €55.00k | Veri yok | |
| Employee Representative Member of the Supervisory Board | 1.6yrs | Veri yok | Veri yok | |
| Member of the Supervisory Board | 6.5yrs | €52.00k | Veri yok | |
| Employee Representative Deputy Chairman of Supervisory Board | 5yrs | €40.50k | Veri yok | |
| Employee Representative Member of Supervisory Board | 4.6yrs | €36.00k | Veri yok | |
| Member of Supervisory Board | 3.4yrs | Veri yok | Veri yok | |
| Employee Representative Member of the Supervisory Board | 2.6yrs | €19.20k | Veri yok | |
| Employee Representative Member of the Supervisory Board | 1.6yrs | Veri yok | Veri yok |
3.4yrs
Ortalama Görev Süresi
53yo
Ortalama Yaş
Deneyimli Yönetim Kurulu: AFX 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 3.4 yıldır).